DELAXIN

Post-LOE

methocarbamol

Ferndale Pharma Group

ANDAORALTABLET

Approved

Aug 1977

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

DELAXIN (methocarbamol) by Ferndale Pharma Group is clinical pharmacology the mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (cns) depression. First approved in 1977.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber. Pharmacokinetics In…

Indications

Worked on DELAXIN at Ferndale Pharma Group? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.